First Trust Advisors LP purchased a new position in shares of LogicBio Therapeutics Inc (NASDAQ:LOGC) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 14,399 shares of the company’s stock, valued at approximately $156,000. First Trust Advisors LP owned 0.06% of LogicBio Therapeutics at the end of the most recent reporting period.
Several other large investors have also modified their holdings of the company. Stanley Laman Group Ltd. bought a new stake in shares of LogicBio Therapeutics during the second quarter worth approximately $254,000. Charles Schwab Investment Management Inc. boosted its stake in LogicBio Therapeutics by 9.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 22,484 shares of the company’s stock valued at $293,000 after acquiring an additional 1,969 shares during the last quarter. Board of Trustees of The Leland Stanford Junior University boosted its stake in LogicBio Therapeutics by 4.4% in the second quarter. Board of Trustees of The Leland Stanford Junior University now owns 949,443 shares of the company’s stock valued at $12,343,000 after acquiring an additional 40,199 shares during the last quarter. BlackRock Inc. grew its holdings in LogicBio Therapeutics by 23.2% during the 2nd quarter. BlackRock Inc. now owns 451,723 shares of the company’s stock worth $5,873,000 after acquiring an additional 85,079 shares during the period. Finally, Vanguard Group Inc. grew its holdings in LogicBio Therapeutics by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 277,859 shares of the company’s stock worth $3,612,000 after acquiring an additional 7,588 shares during the period. Institutional investors own 55.88% of the company’s stock.
Shares of LOGC stock opened at $7.66 on Friday. The stock has a market cap of $175.60 million, a PE ratio of -2.52 and a beta of 0.91. The stock has a 50-day moving average of $9.26 and a 200-day moving average of $11.13. The company has a debt-to-equity ratio of 0.18, a current ratio of 15.72 and a quick ratio of 15.72. LogicBio Therapeutics Inc has a one year low of $6.34 and a one year high of $20.07.
Several analysts have commented on LOGC shares. Zacks Investment Research cut shares of LogicBio Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 14th. William Blair restated a “buy” rating on shares of LogicBio Therapeutics in a research report on Tuesday, November 12th. ValuEngine raised LogicBio Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, October 29th. Finally, Chardan Capital reiterated a “buy” rating and issued a $20.00 price objective on shares of LogicBio Therapeutics in a report on Thursday, August 15th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $18.67.
About LogicBio Therapeutics
LogicBio Therapeutics, Inc, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect.
Recommended Story: What does a bar chart display?
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.